肝细胞癌冷冻消融术后早期复发的危险因素

目的:探讨肝细胞癌(hepatocellular carcinoma,HCC)患者冷冻消融术后影响早期复发的相关危险因素.方法:回顾分析90例直径≤5.0 cm的HCC行冷冻消融治疗后复发的患者的临床资料,分析影响冷冻消融术后早期复发的危险因素.结果:本组患者随访8-47(平均随访时间21.9±10.1)mo,共有57...     

肝细胞癌患者肝移植术后复发的危险因素及预后分析

目的探讨肝细胞癌(HCC)患者肝移植术后肿瘤复发和死亡的危险因素,了解患者生存情况。方法选取2005年1月-2019年2月于解放军总医院第五医学中心行肝移植的391例HCC患者。根据肝移植术后HCC是否复发分为HCC复发组(n=78)和无复发组(n=313)。计量资料两组间比较采用t检验或Mann-Whitney U检验;计数资料两组间比较采用χ2检验。利用单因素和多因素Cox比例风险回归模型分析肝移植术后患者HCC复发和死亡的危险因素。应用Kaplan-Meier法分析生存情况,并通过受试者工作特征曲线(ROC曲线)分析肝移植术后肿瘤死亡相关危险因素的预测价值。结果 391例HCC肝移植患者的中位随访时间2年,其中78例(19.95%)患者出现HCC复发。肝移植术后患者肿瘤复发和死亡的独立危险因素包括术前AFP水平 200 ng/ml[风险比(HR)=2.52,95%可信区间(95%CI):1.58～4.03,P 0.001; HR=2.99,95%CI:1.59～5.62,P 0.001]、肿瘤直径总和(HR=1.20,95%CI:1.12～1.28,P 0.001; HR=1.10,95%CI:1.02～1.17,P=0.002)、血管侵犯(HR=1.15,95%CI:1.04～1.26,P=0.016; HR=1.10,95%CI:1.03～1.18,P=0.004)。HCC肝移植患者术后1、5和10年总生存率分别为94.8%、84.2%和83.5%; 1、5和10年无瘤生存率分别为84.0%、75.1%和75.1%。AFP、大血管侵犯、BMI与肿瘤直径总和联合因素对于HCC复发患者死亡有一定的预测价值(ROC曲线下面积为0.789,95%CI:0.719～0.858)。结论肝移植术前肿瘤生物学特征是肝移植术后肿瘤复发的关键因素。     

原发性肝癌术后早期复发的危险因素分析

目的：探讨原发性肝癌（PLC）患者术后早期复发的危险因素。方法在51例 PLC 患者,选取17项临床和组织病理学参数,分析 PLC 术后早期复发的相关因素。结果发现血清 AST 水平（P〈0.001）、是否伴有肝硬化（P〈0.001）、肿瘤包膜是否完整（P=0.003）和血管侵犯（P=0.006）与早期复发相关;通过 Kaplan-Meier 法和 Cox 风险比例模型筛选发现有肝硬化（风险比=2.865,95%可信区间为1.846~8.466,P〈0.001）、肿瘤包膜缺失（风险比=3.357,95%可信区间为1.526~6.949,P=0.002）和血管侵犯（风险比=2.230,95%可信区间为1.094~4.548,P=0.027）是 PLC 术后早期复发的独立危险因素。结论对于有肝硬化、肿瘤包膜缺失和伴有血管侵犯等危险因素的 PLC 患者,术后应加强随访,以期及早发现肿瘤复发并给予及时的治疗。     

肝细胞癌术后复发的临床病理

目的探讨影响人肝细胞癌术后复发和预后的临床病理危险因素．方法应用单因素或多因素显著性检验及Ｗｉｌｃｏｘｏｎｃｏｘ回归检验，对１５６例治疗性切除人肝细胞癌病例进行回顾性临床病理学（包括性别、瘤数、瘤大小、肝包膜浸润及门静脉累及等）分析．结果肝细胞癌１５６例中，首发癌７３例，复发癌８３例，术后复发率５３２％，其中亚临床可再切除复发肝癌６５例，再切除率为７８３％（６５／８３）．全组病例１、２、３、４、５年术后生存率分别为６８４％，５７３％，４６７％，３１５％和２８６％．肝癌术后复发相关的临床病理因素主要是：男性，多个，瘤体大（直径＞５ｃｍ），包膜浸润和门静脉累及等，术后复发率高，无瘤活存时间短（Ｐ＜００５）．结论肝细胞癌术后复发的危险因素为男性，多个（＞２个），体积大（直径＞５ｃｍ），包膜癌浸润和肝门血管癌栓形成等．肝细胞癌术后复发主要为单中心性，肝右前叶为术后复发多发肝段．     

HBV相关肝细胞癌的危险因素

目前,HBV感染是全球公认的肝细胞癌(HCC)主要危险因素。然而,在乙型肝炎-肝硬化-肝癌的发展过程中,还有其他的辅助因素,如性别、年龄、家族史、ALT/AST、吸烟饮酒史、代谢综合征以及合并HCV、HIV感染等可能独立或与HBV协同促进HCC的发生。综述了HBV相关HCC的危险因素研究进展。     

慢性乙型肝炎相关性肝细胞癌的危险因素研究进展

慢性乙型病毒性肝炎是我国肝癌的最主要病因,肝癌的早筛早治有利于改善患者的预后。目前还没有可以直接诊断的早期标志物,因此对慢性乙型肝炎患者发生肝细胞癌的危险因素研究,具有重要意义。本篇综述主要总结了慢性乙型肝炎进展至肝癌的危险因素。慢乙肝患者在HBsAg阴转后仍需监测肝癌的发生。     

肝细胞癌发病危险因素Logistic回归分析*

目的 探讨肝细胞癌发病的危险因素。方法 2019年1月～2021年1月青海省第四人民医院消化科和青海大学附属医院介入科确诊为肝细胞癌(HCC)患者150例,收集患者临床资料,采用Logistic回归分析法行单因素和多因素分析。结果 单因素Logistic回归分析显示,年龄、肝癌家族史、饮酒史、血小板计数、HBsAg阳性、血清HBV DNA和肝硬化等7个因素具有显著性意义,多因素Logistic回归分析显示,年龄(P=0.001,OR=1.077)、肝癌家族史(P=0.008,OR=4.351)、血小板计数异常(P=0.004,OR=9.071)、HBsAg阳性(P＜0.001,OR=16.418)、HBV DNA(P=0.004,OR=6.345)和肝硬化(P＜0.001,OR=9.315)为HCC发生的独立危险因素。结论 了解HCC发生的危险因素有助于预防,及时抗病毒和预防肝硬化的发生可能非常有意义。     

糖尿病与丙型肝炎相关的肝细胞癌复发相关联

据医业网10月6日报道（原载Am J Gastroenterol 2007；102：1939-1946），糖尿病是与丙型肝炎病毒感染（HCV）相关的肝细胞癌患者不良结果的预测因素。 日本金泽大学的Shuichi Kaneko博士指出，糖尿病不仅是肝细胞癌发生的风险因素，也是手术后复发的风险因素。他们对有乙型肝炎和／或丙型肝炎并因肝细胞癌接受了手术治疗的90例患者进行了回顾性研究。[第一段]     

Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma

Background: Postoperative complications may adversely affect oncological outcomes. The aim of this study was to evaluate the impact of postoperative complications on early-phase recurrence after curative resection for hepatocellular carcinoma(HCC).Methods: We included 145 HCC patients who underwent initial and curative resection between January2004 and December 2013. Postoperative complications of grade III or higher based on Clavien–Dindo classification were defined as clinically relevant postoperative complications. Recurrence within two years after hepatectomy was defined as early-phase recurrence.Results: Thirty-eight patients(26%) developed postoperative complications. The only predictive factor for postoperative complication was longer operative duration(P = 0.037). The disease-specific survival rate of patients with complication was lower than that of patients without complications(P = 0.015). Earlyphase recurrence was observed in 20/38(53%) patients who suffered postoperative complications and36/107(34%) patients with no complications, which was statistically significant(P = 0.039). Multivariate analysis identified four factors contributing to early-phase recurrence: high serum AFP level(P = 0.042),multiple tumors(P 0.001), poor differentiation(P = 0.036) and presence of postoperative complication(P = 0.039).Conclusions: Postoperative complication is an independent prognostic factor for early-phase recurrence after curative resection of HCC. Close observation of patients with postoperative complications may be a necessary treatment strategy for HCC.     

Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma

AIM:To investigate the clinicopathological riskfactors for immediate post-operative fatal recurrenceof hepatocellular carcinoma (HCC),which may havepractical implication and contribute to establishinghigh risk patients for pre-or post-operative preventivemeasures against HCC recurrence.METHODS:From June 1994 to May 2004,269 patientswho received curative resection for HCC were reviewed.Of these patients,those who demonstrated diffuse intra-hepatic or multiple systemic recurrent lesions within 6mo after surgery were investigated (fatal recurrencegroup).The remaining patients were designated as thecontrol group,and the two groups were compared forclinicopathologic risk factors.RESULTS:Among the 269 patients reviewed,30patients were enrolled in the fatal recurrence group.Among the latter,20 patients showed diffuse intra-hepatic recurrence type and 10 showed multiple systemicrecurrence type.Multivariate analysis between the fatalrecurrence group and control group showed that pre-operative serum alpha-fetoprotein (AFP) level wasgreater than 1000 μg/L (P=0.02; odds ratio=2.98),tumor size greater than 6.5 cm (P=0.03; OR=2.98),and presence of microvascular invasion (P=0.01;OR=4.89) were the risk factors in the fatal recurrencegroup.The 48.1% of the patients who had all the threerisk factors and the 22% of those who had two riskfactors experienced fatal recurrence within 6 mo aftersurgery.CONCLUSION:Three distinct risk factors for immediatepost-operative fatal recurrence of HCC after curativeresection are pre-operative serum AFP level>1000 μg/L, tumor size>6.5 cm,and microvascular invasion.Thehigh risk patients with two or more risk factors should bethe candidates for various adjuvant clinical trials.     

Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy

AIM: To evaluate the factors affecting the early tumor recurrence within one year in cirrhotic patients having a single small hepatocellular carcinoma (HCC) after complete tumor necrosis by radiofrequency ablation (RFA) therapy. METHODS: Thirty patients with a single small HCC received RFA therapy by a RFA 2000 generator with LeVeen needle. Tri-phase computerized tomogram was followed every 2 to 3 mo after RFA. The clinical effects and tumor recurrence were recorded. RESULTS: The initial complete tumor necrosis rate was 86.7%. Twenty-two patients were followed for more than one year. The local and overall recurrence rates were 13.6% and 36.4%, 33.3% and 56.2%, 46.6% and 56.2% at 12, 24 and 30 mo, respectively. No major complication or procedure-related mortality was found. The risk factors for early local tumor recurrence within one year were larger tumor size, poor pathologic differentiation of tumor cells and advanced tumor staging. The age of patients with new tumor formation within one year was relatively younger (55.1±8.3 vs 66.7±10.8, P= 0.029). CONCLUSION: Large tumor size, poor pathologic differentiation of tumor cells and advanced tumor staging are the risk factors for early local tumor recurrence within one year, and young age is the positive predictor for new tumor formation within one year.     

Risk factors for early recurrence of small hepatocellular carcinoma after curative resection

BACKGROUND:Poorer prognosis is seen in patients with hepatocellular carcinoma (HCC) after curative hepatic resection with early recurrence (≤1 year) than in those with late recurrence (>1 year).This study aimed to identify risk factors for postoperative early recurrence of small HCC (≤3 cm in diameter).METHODS:The study population consisted of 158 patients who underwent curative resection for small HCC between January 2002 and July 2004.Risk factors for early recurrence were analyzed.RESULTS:Thirty-three (2...     

Hepatocellular carcinoma recurrence after liver transplantation: Risk factors,screening and clinical presentation

Liver transplantation is the best treatment option for cirrhotic patients with earlystage hepatocellular carcinoma, but it faces the problem of scarcity of donors and the risk of tumor recurrence, which affects between 15% and 20% of the cases,despite the use of restrictive criteria. The risk of recurrence depends on a number of factors, related to the tumor, the patient, and the treatment, which are discussed in this review. Some of these factors are already well established, such as the histopathological characteristics of the tumor, Alpha-fetoprotein(AFP)levels, and waiting time. Other factors related to the biological behavior of the tumor and treatment should be recognized because they can be used in the refinement of the selection criteria of transplant candidates and in an attempt to reduce recurrence. This review also discusses the clinical presentation of recurrence and its prognosis, contributing to the identification of a subgroup of patients who may have better survival, if they are timely identified and treated.Development of recurrence after the first year, with AFP levels ≤ 100 ng/mL, and single site capable of locoregional therapy are associated with better survival after recurrence.     

Tumor vaccine against recurrence of hepatocellular carcinoma

AIM: To investigate the effects of autologous tumor vaccine on recurrence of hepatocellular carcinoma (HCC). METHODS: Sixty patients with HCC who had undergone curative resection, were randomly divided into HCC vaccine group and control group. Three vaccinations at 2-wk intervals were performed after curative hepatic resection. Delayed-type- hypersensitivity (DTH) test was performed before and after vaccination. Primary endpoints were the time of recurrence. RESULTS: Four patients in control group and 6 patients in HCC vaccine group were withdrawn from the study. The vaccine containing human autologous HCC fragments showed no essential adverse effect in a phase II clinical trial and 17 of 24 patients developed a DTH response against the fragments. Three of 17 DTH-positive response patients and 5 of 7 DTH- negative response patients had recurrences after curative resection. After the operation, 1-, 2- and 3-year recurrence rates of HCC vaccine group were 16.7%, 29.2% and 33.3%, respectively. But, 1-, 2- and 3-year recurrence rates of the control group were 30.8%, 53.8% and 61.5%, respectively. The time before the first recurrence in the vaccinated patients was significantly longer than that in the control patients (P<0.05). CONCLUSION: Autologous tumor vaccine is of promise in decreasing recurrence of human HCC.     

Local recurrence of hepatocellular carcinoma after radiofrequency ablation

A 51-year-old Chinese male with a 20-year history of hepatitis B was diagnosed with hepatocellular carcinoma in the right anterior portion of the liver, sized 3.5 cm × 3.2 cm, and was treated with radiofrequency ablation (RFA) on December 18, 2001. The patient did not receive antiviral therapy for hepatitis B virus after RFA. The treated lesion reduced gradually and reached its minimum size of 1.7 cm × 1.5 cm seven years later on November 18, 2008. However computed tomography findings revealed that a recurr...